Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | FABP7 | O15540 | 1/20 | 0.32 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.32 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.32 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.31 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.31 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.31 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9942281 | 0.81 | PARP1 (0.41) | LMNASMN1; SMN2EPHX1 | |
| SCHEMBL15606432 | 0.81 | PARP1 (0.41) | LMNASMN1; SMN2EPHX1 | |
| SCHEMBL15606366 | 0.81 | PARP1 (0.41) | LMNASMN1; SMN2EPHX1 | |
| SCHEMBL13741302 | 0.80 | EPHX1 (0.33) | HTR6FABP7FABP5TSHRSMN1; SMN2 | |
| SCHEMBL376354 | 0.79 | TPSAB1 (0.36) | HTR6SLC6A1SLC6A11TSHRLMNA | |
| SCHEMBL5073006 | 0.78 | CHRNB2 (0.37) | — | |
| SCHEMBL375940 | 0.77 | KLK7 (0.50) | TSHRSMN1; SMN2L3MBTL1 | |
| SCHEMBL9937434 | 0.75 | CHRM2 (0.37) | FABP7FABP5TSHRCHRM2CHRM4 | |
| SCHEMBL15542301 | 0.75 | SLC6A1 (0.36) | HTR6SLC6A1SLC6A11TSHRLMNA | |
| SCHEMBL3272707 | 0.75 | SLC6A1 (0.36) | HTR6SLC6A1SLC6A11TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069291-B1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-12-20 | — | — | EP | disclosed |
| EP-2864318-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | Chroma Therapeutics Ltd. (GB) | 2015-04-29 | — | — | EP | disclosed |
| US-20140010762-A1 | IMAGING AGENTS | CHROMA THERAPEUTICS LTD (GB) | 2014-01-09 | — | — | US | disclosed |
| WO-2014001802-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2014-01-03 | — | — | WO | disclosed |
| EP-2651454-A1 | IMAGING AGENTS | Chroma Therapeutics Ltd. (GB) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080705-A1 | IMAGING AGENTS | CHROMA THERAPEUTICS LTD (GB) | 2012-06-21 | — | — | WO | disclosed |
| EP-2079743-B1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-2295410-A1 | HDAC inhibitor | Chroma Therapeutics Limited (GB) | 2011-03-16 | — | — | EP | disclosed |
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-08-26 | — | — | US | disclosed |
| EP-2079743-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | Chroma Therapeutics Limited (GB) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008050096-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140010762-A1 | IMAGING AGENTS | CES1, CES2, NCEH1 | HTR6 2862/4885FABP7 497/4885FABP5 1523/4885 |
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | PLK2, PLK4, PLK3 | HTR6 1271/4885FABP7 4657/4885FABP5 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.